Clinical trials: sponsored by University of Oxford
Melanoma
Docetaxel With or Without AZD6244 in Melanoma
This is a randomised, double-blind placebo controlled phase 2 trial. Patient will be randomly assigned 1:1 between 2 treatment arms.
- Trial name
- DOC-MEK (NCT01256359)
- Testing
- Docetaxel and AZD6244
- Where
- United Kingdom
- Volunteers
- 83 people
- Sponsor
- University of Oxford
Oesophageal Adenocarcinoma, Squamous Cell Carcinoma
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
This Phase I study will test the combination of a novel ATR inhibitor (M6620) with chemoradiotherapy in oesophageal cancer; utilizing three experimental cohorts (Stage A1, A2 and B).
- Conditions
- Oesophageal Adenocarcinoma, Squamous Cell Carcinoma, Solid Tumor
- Trial name
- CHARIOT (NCT03641547)
- Testing
- M6620, Cisplatin, Capecitabine
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Oxford
Oesophageal Cancer
Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer
This is a feasibility study testing the use of the Cytosponge™ device in patients with known oesophageal cancer treated with pre-operative or definitive chemoradiation.
- Trial name
- CYTOFLOC (NCT03529669)
- Testing
- Cytosponge™
- Where
- 11 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Malaria, Falciparum
Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
This study is a multi-centre, open-label randomised trial to assess the efficacy, safety and tolerability of the Triple ACT artemether-lumefantrine+amodiaquine (AL+AQ) compared to the ACT artemether-lumefantrine (AL) in…
- Trial name
- TACT-CV (NCT03355664)
- Testing
- ACT, TACT
- Where
- 4 sites in Cambodia, Vietnam
- Volunteers
- 310 people
- Sponsor
- University of Oxford
Solid Tumor, Colorectal Cancer
MEK and MET Inhibition in Colorectal Cancer
This trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer.
- Trial name
- MErCuRIC1 (NCT02510001)
- Testing
- PF-02341066, PD-0325901, Binimetinib
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- University of Oxford
Osteosarcoma
A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
This is a Bayesian designed multi-arm, multi-centre, open label phase II study. The target sample size of 40 patients will be recruited from up to 8 EU countries, but this may be revised in light of the interim analysis.
- Trial name
- MEMOS (NCT02441309)
- Testing
- Mifamurtide, Ifosfamide
- Where
- 8 sites in Germany, Italy and 3 more
- Volunteers
- 8 people
- Sponsor
- University of Oxford
Malnutrition, Infection
Effectiveness of Supplementary Feeding During Infection Among Moderately Malnourished Children
The purpose of this study is to determine whether an outpatient-based strategy of short-term, ready to use supplementary food (RUSF) among moderately malnourished children with acute infections achieves greater improvement in…
- Trial name
- MODMAL (NCT00890695)
- Testing
- Ready to use supplementary food (RUSF)
- Where
- 2 sites in Kenya
- Volunteers
- 64 people
- Sponsor
- University of Oxford